Researchers successfully bypass the mucus barrier in lungs for the first time.
The mucus barrier protects foreign materials and bacteria from entering and/or infecting lungs. In healthy lungs, inhaled matter is typically trapped in airway mucus and subsequently swept away from the lungs via beating activities of cilia, or small, hairlike strands, to the stomach to be eventually degraded. Unfortunately, this essential protective mechanism also prevents many inhaled therapeutics, including gene-based medicine, from reaching their target. Now, researchers from the Johns Hopkins University and the Federal University of Rio de Janeiro state that they have designed a DNA-loaded nanoparticle which can pass through the mucus barrier covering conducting airways of lung tissue, proving the concept, they say, that therapeutic genes may one day be delivered directly to the lungs to the levels sufficient to treat cystic fibrosis (CF), chronic obstructive pulmonary disease, asthma and other life-threatening lung diseases. The study is published in the journal Proceedings of the National Academy of Sciences.
The current study, which used human airway mucus and small animals, was designed as a proof-of-concept study demonstrating that placing corrective or replacement genes or drugs inside a man-made biodegradable nanoparticle ‘wrapper’ that patients inhale could penetrate the mucus barrier and one day be used to treat serious lung disorders. What’s more, because a single dose might theoretically last for several months, patients would experience fewer side effects common to drugs that must be taken regularly over long stretches of time. The researchers state that to their knowledge this is the first biodegradable gene delivery system that efficiently penetrates the human airway mucus barrier of lung tissue.
The lab explain that their work with nanoparticles grew out of failed efforts to deliver treatments to people with lung diseases. In patients with CF previous studies show that they experience a buildup of excess mucus caused by impaired ciliary beating, resulting in an ideal breeding ground for chronic bacterial infection and inflammation. This pathogenic process not only worsens patients’ quality of life, and often puts patients in life-threatening situations, it also makes the airway mucus harder to overcome by inhaled therapeutic nanoparticles.
Most of the existing drugs for CF help clear infections, however the team note that, they do not solve the disease’s underlying problems. A couple of recently approved drugs designed to target the underlying cause of CF require daily treatment for the entire lifetime and can benefit only a subpopulation of patients with specific types of mutations. The current study demonstrates that delivering normal copies of CF-related genes or corrective genes via the mucus-penetrating DNA-loaded nanoparticles could mediate production of normal, ‘functional’ proteins long term. The team foresee that this could eventually become an effective therapy for the lungs of patients, regardless of the mutation type.
The team note that numerous nonviral, synthetic systems have been widely tested. However, previous research had shown that most of the nonviral, DNA-loaded nanoparticles possess positive charge that caused them to adhere to negatively charged biological environments, in this case the mucus covering the lung airways. In other words, conventional nanoparticles are too sticky to avoid unwanted off-target interactions during their journey toward the target cells. Further, these particles tend to rapidly aggregate in physiological conditions, rendering them too large to penetrate the mesh of airway mucus.
For the current study the team developed a simple method to densely coat the nanoparticles with a nonsticky polymer called PEG, neutralized the charge and created a nonsticky exterior. They showed that these nanoparticles retained their sizes at a physiological environment and are capable of rapidly penetrating human airway mucus freshly collected from patients visiting the Johns Hopkins Adult Cystic Fibrosis Program. The lab also made the whole delivery system biodegradable so that it would not build up inside the body.
To test whether the system provides efficient gene transfer to the lungs of animals, the researchers packed them with a gene that makes light-generating proteins once delivered into the target cells. The data findings showed that inhaled delivery of the genes via the mucus-penetrating nanoparticles resulted in widespread production of the protein to levels superior to gold-standard, nonviral platforms, including a clinically tested system. In addition, the results showed that the treated lungs lit up for up to four months after a single dosing.
The researchers surmise that with one dose there is gene expression, i.e., production of therapeutic proteins, for several months. They go on to add that the nanoparticles did not appear to show any adverse effects, such as increased lung inflammation.
The team caution that more animal studies are needed to confirm and refine their proof-of-concept study, and that treatment of human disorders with nanowrapped therapies is years away.
Source: Johns Hopkins Medicine